Acquisitions

Novartis to Buy Avidity Biosciences for $12 Billion, Adding Muscle-Targeted RNA Drugs

The purchase bets on Avidity’s muscle-targeted RNA platform as Novartis pushes deeper into rare neuromuscular disease.